Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Nebivolol and Metoprolol With Exercise and Angiotensin II in Hypertensive Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Stage I hypertension (140-159/90-99 mmHg)~* Men and women age 18-65~Exclusion Criteria:~* Congestive heart failure or coronary artery disease~* Blood pressure averaging \>159/99 mmHg or resting heart rate \< 55 bpm~* Serum creatinine \> 1.4 mg/dL~* Asthma or chronic obstructive pulmonary diseases~* Left ventricular hypertrophy by echocardiography or ECG~* Pregnancy~* Hypersensitivity to beta blockers, microbubble contrast agents, or angiotensin~* Any history of substance abuse (other than tobacco)~* Concomitant drug treatment which raises endogenous nitric oxide levels such as nitrates or phosphodiesterase V inhibitors (Viagra, Levitra, or Cialis)~* History of symptomatic bradycardia or heart block

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Initial treatment with metoprolol (Type: ACTIVE_COMPARATOR): The subject will be started on metoprolol succinate (Toprol XL) 100-300mg daily, which he or she will continue for a period of 12 weeks. Following the 12-week treatment period, the procedures listed below will be performed. After completion of the study procedures, the medication will be discontinued. There will be a 2-week washout period. Following washout, the subject will be started on nebivolol (Bystolic) 5-20mg daily, which he or she will continue for a period of 12 weeks. Following the 12-week treatment period, the procedures listed below will be performed. After completion of the study procedures, the medication will be discontinued.
- Initial treatment with nebivolol (Type: ACTIVE_COMPARATOR): The subject will be started on nebivolol (Bystolic) 5-20mg daily, which he or she will continue for a period of 12 weeks. Following the 12-week treatment period, the procedures listed below will be performed. After completion of the study procedures, the medication will be discontinued. There will be a 2-week washout period. Following washout, the subject will be started on metoprolol succinate (Toprol XL) 100-300mg daily, which he or she will continue for a period of 12 weeks. Following the 12-week treatment period, the procedures listed below will be performed. After completion of the study procedures, the medication will be discontinued.

Based on this trial design, predict the completion outcome and termination type (if applicable).